Survival in overweight patients with advanced pancreatic carcinoma: A multicentre cohort study

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Kasenda, Benjamin ^a,b   Bass, Annatina ^a   Koeberle, Dieter ^c   Pestalozzi, Bernhard ^d   Borner, Markus ^e   Herrmann, Richard ^a   Jost, Lorenz ^f   Lohri, Andreas ^f   Hess, Viviane ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Baseline; BMI; Body mass index; CA 19 9; Pancreatic cancer; Prognostic factors; Survival

Indexed keywords

GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY MASS; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PANCREAS CARCINOMA; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; CANCER STAGING; CLINICAL TRIAL; COMORBIDITY; COMPLICATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PANCREATIC NEOPLASMS; PATHOLOGY; SURVIVAL; SWITZERLAND;

AGED; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OBESITY; OVERWEIGHT; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SWITZERLAND;

EID: 84929656035     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-728     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
3. Hawes RH, Xiong Q, Waxman I, Chang KJ, Evans DB, Abbruzzese JL: A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol 2000, 95:17-31.
4. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, Abbruzzese JL: Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009, 301:2553-2562.
5. Larsson SC, Wolk A: Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies. Br J Cancer 2012, 106:603-607.
6. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS: Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001, 286:921-929.
7. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D: Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005, 294:2872-2878.
8. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, Herrmann R: CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008, 9:132-138.
9. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D: CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 2005, 93:740-743.
10. McWilliams RR, Matsumoto ME, Burch PA, Kim GP, Halfdanarson TR, de Andrade M, Reid-Lombardo K, Bamlet WR: Obesity adversely affects survival in pancreatic cancer patients. Cancer 2010, 116:5054-5062.
11. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, Terris MK: Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004, 22:446-453.
12. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB 3rd, Macdonald JS, Fuchs CS: Influence of body mass index on outcomes and treatmentrelated toxicity in patients with colon carcinoma. Cancer 2003, 98:484-495.
13. Newman SC, Lees AW, Jenkins HJ: The effect of body mass index and oestrogen receptor level on survival of breast cancer patients. Int J Epidemiol 1997, 26:484-490.
14. WHO: BMI Classification. In Vol. Website Accessed on 3rd July 2013. WHO; http://apps.who.int/bmi/index.jsp?introPage=intro_3.html.
15. Altman DG, McShane LM, Sauerbrei W, Taube SE: Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med 2012, 9:e1001216.
16. Royston P, Altman DG, Sauerbrei W: Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006, 25:127-141.
17. Spratt M, Carpenter J, Sterne JA, Carlin JB, Heron J, Henderson J, Tilling K: Strategies for multiple imputation in longitudinal studies. Am J Epidemiol 2010, 172:478-487.
18. Kenward MG, Carpenter J: Multiple imputation: current perspectives. Stat Methods Med Res 2007, 16:199-218.
19. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD: Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001, 54:774-781.
20. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009, 27:5513-5518.
21. Klebanoff MA, Cole SR: Use of multiple imputation in the epidemiologic literature. Am J Epidemiol 2008, 168:355-357.
22. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR: Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009, 338:b2393.
23. Calle EE, Kaaks R: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4:579-591.
24. Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, Qian ZR, Rubinson DA, Stampfer MJ, Giovannucci EL, Wolpin BM: Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol 2013, 31:4229-4234.
25. LeRoith D, Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 2003, 195:127-137.
26. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, Muti P, Lenner P, Koenig KL, Biessy C, Krogh V, Riboli E, Shore RE, Stattin P, Berrino F, Hallmans G, Toniolo P, Kaaks R: Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer 2004, 108:262-268.
27. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E: Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000, 92:1592-1600.
28. de Berrington GA, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee IM, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A: Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010, 363:2211-2219.
29. Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O: Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev 2012, 8:CD008465.